← All Viridian Therapeutics, Inc\de filings

Viridian Therapeutics, Inc\de Form 4 insider transactions

NASDAQ
VRDN
Viridian Therapeutics, Inc\de
Form 4: Viridian Therapeutics Director Sarah Gheuens Acquires Stock Options
Director Sarah Gheuens acquired stock options for 21,000 shares of Viridian Therapeutics, Inc.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
Form 4: Viridian Therapeutics Director Arlene Morris Acquires Stock Options
Director Arlene Morris acquired 21,000 stock options in Viridian Therapeutics, Inc. on June 26, 2024, according to a Form 4 filing with the SEC.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
Form 4: Viridian Therapeutics Director Jennifer K. Moses Granted Stock Options
Director Jennifer K. Moses acquired 21,000 stock options in Viridian Therapeutics, Inc. on June 26, 2024, vesting in full by June 26, 2025, or the 2025 annual meeting.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
Form 4: Viridian Therapeutics Director Peter Harwin Granted Stock Options
Director Peter Evan Harwin of Viridian Therapeutics, Inc. was granted stock options for 21,000 shares on June 26, 2024, according to a Form 4 filing with the SEC.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
Form 4: Viridian Therapeutics Director Tomas Kiselak Granted Stock Options
Director Tomas Kiselak of Viridian Therapeutics, Inc. was granted stock options for 21,000 shares on June 26, 2024, according to a Form 4 filing.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
Form 4: Fairmount Funds Management Transfers Viridian Therapeutics Shares Between Healthcare Funds
Fairmount Funds Management LLC transferred shares of Viridian Therapeutics common stock and Series A Non-Voting Convertible Preferred Stock from Fairmount Healthcare Fund LP to Fairmount Healthcare Fund II LP on March 28, 2024, as part of the wind down of Fund I.